SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence by den Hartog, G. et al.
M A J O R  A R T I C L E
1452 • jid 2020:222 (1 November) • den Hartog et al
The Journal of Infectious Diseases
SARS-CoV-2–Specific Antibody Detection for 
Seroepidemiology: A Multiplex Analysis Approach 
Accounting for Accurate Seroprevalence
Gerco den Hartog,1,  Rutger M. Schepp,1 Marjan Kuijer,1 Corine GeurtsvanKessel,2 Josine van Beek,1 Nynke Rots,1 Marion P. G. Koopmans,2  
Fiona R. M. van der Klis,1 and Robert S. van Binnendijk1
1Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, Bilthoven, the Netherlands, and 2Department of Viroscience, Erasmus 
Medical Center, Rotterdam, the Netherlands
Background. The COVID-19 pandemic necessitates better understanding of the kinetics of antibody production induced by 
infection with SARS-CoV-2. We aimed to develop a high-throughput multiplex assay to detect antibodies to SARS-CoV-2 to assess 
immunity to the virus in the general population.
Methods. Spike protein subunits S1 and receptor binding domain, and nucleoprotein were coupled to microspheres. Sera collected 
before emergence of SARS-CoV-2 (n = 224) and of non-SARS-CoV-2 influenza-like illness (n = 184), and laboratory-confirmed cases of 
SARS-CoV-2 infection (n = 115) with various severities of COVID-19 were tested for SARS-CoV-2–specific IgG concentrations.
Results. Our assay discriminated SARS-CoV-2–induced antibodies and those induced by other viruses. The assay specificity 
was 95.1%–99.0% with sensitivity 83.6%–95.7%. By merging the test results for all 3 antigens a specificity of 100% was achieved with 
a sensitivity of at least 90%. Hospitalized COVID-19 patients developed higher IgG concentrations and the rate of IgG production 
increased faster compared to nonhospitalized cases.
Conclusions. The bead-based serological assay for quantitation of SARS-CoV-2–specific antibodies proved to be robust and can 
be conducted in many laboratories. We demonstrated that testing of antibodies against multiple antigens increases sensitivity and 
specificity compared to single-antigen–specific IgG determination.
Keywords.  COVID-19; IgG; spike S1; RBD; nucleoprotein; endemic coronavirus; multiplex bead-based immune assay; 
 specificity; sensitivity; influenza-like Illness (ILI).
Coronavirus disease 2019 (COVID-19) caused by the newly 
emerged severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) has resulted in a pandemic in a largely immune-naive 
population. The presence of specific antibodies is currently being 
investigated to assess the induction of an immune response in pa-
tients and to assess the degree of exposure and immunity in the 
general population [1–3]. As it is a recently emerged coronavirus 
variant, the kinetics and degree of immunity induced following 
contact with the virus and COVID-19 disease are largely unknown.
SARS-CoV-2 expresses a spike protein, highly similar to spike 
of SARS-CoV, which binds to angiotensin converting enzyme 
2 (ACE2) [4, 5]. Binding of antibodies to the receptor binding 
domain (RBD) of spike neutralizes the ability of the virus to in-
fect cells [6]. In addition, antibodies are detected against other 
viral proteins, including nucleoprotein (N) [7]. N is shielded 
within the virion and therefore N-specific antibodies are prob-
ably unable to neutralize the virus. Although N may not be 
involved in neutralization of the virus, antibodies to N could 
provide an indicator of exposure to the virus. Antibodies to N 
induced by SARS-CoV reportedly recognize N of SARS-CoV-2 
but not of seasonal coronaviruses [8].
Estimates of the prevalence of seroconversion as proxy for 
protection of the general population may support health de-
cision making, including the decision to lift lockdown meas-
ures. To appropriately apply an assay for serosurveys we need 
to know the precision of the assay, that is the sensitivity and 
specificity, which are variable between currently available tests 
[9, 10]. Performing and sustaining large studies to assess chan-
ging population immunity requires high-throughput screening 
assays that are robust and accurate [11]. Many countries now 
aim to assess the protective status of the general population for 
COVID-19 using antibody assays. To guarantee high specificity, 
the assay should be validated with a representative number of 
sera from patients infected with other coronaviruses and other 
pathogens causing influenza-like illness (ILI), but this is often 
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lacking [11–13]. To date, COVID-19 prevalence of serocon-
verted individuals is relatively low and there is a risk of sig-
nificant overestimation if an assay has insufficient specificity 
(Supplementary Table 1). Thus, high specificity is important at 
this stage [11, 12].
Our laboratory has extensive experience in developing mul-
tiplex assays to quantify antibodies to many bacterial and viral 
pathogens in the general population, of which most are part of 
the national immunization program [1, 14–17]. We developed a 
high-throughput and highly quantitative bead-based multiplex 
immunoassay to assess the prevalence of seropositivity in the 
general population, and also anticipating the introduction of fu-
ture SARS-CoV-2 vaccines. By multiplexing a broader range of 
SARS-CoV-2 antigens in a single assay we may generate a better 
understanding of the proportion of persons that have serocon-
verted. Moreover, in a multiplex assay positivity can be com-
pared among antigens to provide a more detailed evaluation 
of the antibody levels and to enhance assay performance [17]. 
The developed assay was tested on samples from COVID-19 
patients with various severities of disease collected at multiple 
timepoints to determine the kinetics of seroconversion.
METHODS
Serum Samples
Serum samples were obtained from the following cohorts: (1) 
a random selection of individuals (n  =  224) from a national 
(Dutch) cohort representing all age groups and obtained 3 years 
prior to SARS-CoV-2 emergence (Pienter3 study, Netherlands 
trial register number NL5467); (2) individuals (Supplementary 
Table 2) with proven non-SARS-CoV-2 ILI caused by human 
coronaviruses (n  =  110, HCoV ILI) or other viruses (n  =  74, 
non-HCoV ILI) obtained from the National Institute for 
Public Health and the Environment (RIVM), Bilthoven, the 
Netherlands (trial register number NL4666) [18], and from 
Erasmus Medical Center, Rotterdam, collected prior to the 
SARS-CoV-2 outbreak and at least 2 weeks after polymerase 
chain reaction (PCR) detection of the virus; and (3) sera of 115 
laboratory-(PCR) confirmed COVID-19 patients that were 
either hospitalized (n  =  50) or outpatient (n  =  65) (Erasmus 
Medical Center and RIVM, Medical Ethical Committee number 
METC 06/282). Of the nonhospitalized cases, 34% were male 
and the median age was 42.6  years (95% confidence interval 
[CI], 40.0–45.2). Of the hospitalized patients 51% were ad-
mitted to the intensive care unit. Of the ward and ICU patients, 
78% and 75% were male and the mean age was 62.1 years (95% 
CI, 55.5–68.8) and 61.8 years (95% CI, 55.7–97.8), respectively. 
Paired samples, collected between days 3 and 40 after disease 
onset, were available from 73 COVID-19 patients. Ethical ap-
proval was obtained from the Erasmus Medical Center Medical 
Ethical Committee (MEC-2015–306) to anonymously analyze 
the ILI and COVID-19 samples. Informed consent and volun-
tary informed consent were provided where applicable.
Assay Procedure
The steps in assay validation were similar to recently developed 
bead-based multiplex immunoassays for CMV, EBV, and RSV, 
with minor modifications as described below [16, 17]. For the 
multiplex bead-based immune assay the following antigens 
obtained from Sino Biological were used: SARS-CoV-2 mon-
omeric spike S1 (40591-V08H), RBD (40592-V08B), and nu-
cleoprotein (N) (40588-V08B). Microplex fluorescent beads 
were activated in 50 mM 2-(N-morpholino)ethanesulfonic acid 
(MES) pH 5.5. The proteins were diluted to a concentration 
of 0.2 mg/mL in phosphate-buffered saline (PBS) pH 7.4 and 
added at 5 µg per 75 µL of activated beads.
An internal reference sample was created by pooling 13 sera 
of COVID-19 patients with varying immunoglobulin G (IgG) 
concentrations. An arbitrary antibody concentration unit of 
100 was assigned on the basis of the mean fluorescence inten-
sity (MFI) signal in the upper limit of linearity of a 3-fold serial 
dilution of the reference sample.
Sera (25  µL) diluted 1:400 and 1:8000 in SM01 buffer 
(Surmodics) plus 2% fetal calf serum were incubated with 
antigen-coated beads for 45 minutes at room temperature at 
750 rpm in the dark. Following incubation, samples were washed 
3 times with PBS, incubated with phycoerythrin-conjugated 
goat anti-human IgG for 30 minutes and washed. Samples were 
acquired on an LX200 or FM3D (Luminex). MFI was converted 
to arbitrary units (AU/mL) by interpolation from a 5-parameter 
logistic standard curve, using Bioplex Manager 6.2 (Bio-Rad 
Laboratories) software and exported to Microsoft Excel.
Assay Validation
Different batches of antigen-conjugated beads were incubated 
with serially diluted sera to test linearity and parallelism be-
tween bead conjugations, reference, and serum samples. Assay 
robustness was tested by analyzing a serum panel by 3 different 
operators on independent days using 2 different bead and 2 ref-
erence batches. The ability to discriminate IgG concentrations 
between COVID-19 patients and controls was evaluated by re-
ceiver operator characteristic (ROC) analyses. To select the op-
timal assay defaults, both the Youden J statistic, which balances 
between sensitivity and specificity, and a specificity-optimized 
cutoff (specificity of at least 98.5% for low-prevalence settings 
of 5%–10%) were selected.
Data Analyses
Data were entered into GraphPad Prism 8.4.1 to generate graphs 
and perform statistical analyses. Reproducibility of the assay 
was evaluated using R2 and coefficient of variation (%  CV) 
calculated by standard deviation divided by average × 100. 
For the ROC analyses antibody concentrations of cross-sec-
tional Pienter3 participants (n = 224), ILI patients with coro-
navirus (n = 74), or other viral infection (n = 110) were used 
as the negative control group and PCR-confirmed COVID-19 
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the positive group. We selected for serum samples that were 
obtained more than 10  days post onset of disease symptoms 
to meet a reasonable degree of seroconversion, as shown in 
recent reports [8, 19]. Both the Youden J statistic-determined 
cutoff and the specificity-optimized cutoff (specificity of at least 
98.5%) were determined.
To compare differences in concentrations, data were log-
transformed and tested with either a t test between 2 groups, or 
1-way ANOVA and Tukey’s multiple comparison test to com-
pare multiple groups and adjusted P values reported. Antibody 
kinetics was fitted using a nonlinear 4-parameter least square fit 
in Graphpad Prism 8.4.1.
RESULTS
Performance of the Assay
We prepared a reference serum by pooling 13 PCR-confirmed 
COVID-19 sera and tested serial dilutions in the multiplex 
assay consisting of distinct fluorescent beads coupled to 
SARS-CoV-2 nucleoprotein (N), S1, and the S1 subunit RBD 
(Figure 1A). This was repeated for varying batches of beads 
to assess consistency of performance. The assay was able to 
quantify concentrations in a 1000 to 10  000-fold concen-
tration range, using a single dilution of the serum. To reli-
ably quantify antibody concentrations between the reference 
serum and test samples, we confirmed that the reference and 
a selection of samples display the same rate of decline of fluo-
rescence signal with increasing dilutions, which is referred 
to as parallelism (Figure  1B). These data show that the tri-
plex assay is a highly quantitative assay to detect antibodies 
to SARS-CoV-2.
Applying an assay in large population and longitudinal 
studies requires reproducibility of assay results. Therefore, an-
tibody concentrations were determined in independent experi-
ments performed on 6 different days, using a selection of 214 
samples for RBD and 268 samples for N and S1 with different 
concentrations of SARS-CoV-2 antibodies (Figure 1C). In ad-
dition, the reproducibility test was performed by 3 different 
technicians using different bead batches and references to re-
flect the expected maximum variability of the assay over time. 
Comparison of sample data determined on 2 independent as-
says runs resulted in an R2 of 0.982, 0.985, and 0.988 for N, S1, 
and RBD, respectively (Figure 1C). The obtained % CVs were 
19.1, 25.5, and 14.6 for N, S1, and RBD, respectively, showing 
that the assay results were reproducible.
Sensitivity and Specificity
Sera of 115 PCR-confirmed COVID-19 patients after 10 days 
of symptoms were tested in the assay and the results compared 
to a control panel of 408 sera collected prior to the outbreak 
of SARS-CoV-2. In COVID-19 patients, high concentrations 
of IgG were observed to all 3 antigens (Figure  2A). Despite 
clear discrimination of IgG concentrations between groups of 
control and COVID-19 patients, some samples overlapped be-
tween the 2 groups. Therefore, the specificity and sensitivity of 
the assay to discriminate between COVID-19 patients and con-
trols using IgG concentrations was evaluated by an established 
statistical standard to analyze assay performance, the ROC ana-
lyses. For the ROC analyses, concentration data of hospitalized 
and nonhospitalized COVID-19 disease cases were included to 
provide a realistic evaluation of the performance of the assay 
(Figure 2A). The area under the curves ranged from 0.9839 to 
0.9859 (Figure 2B). The ROC generated cutoff concentrations 
of 14.8, 0.85, and 8.21 AU/mL using the ROC Youden J statistic. 
To gain a higher specificity of the assay optimized for a low 
population seroprevalence, the cutoff concentrations were 19.7, 
2.37, and 19.1 for N, S1, and RBD, respectively (Figure 2C). The 
latter cutoffs resulted in a specificity of 98.5%, 99.0%, and 98.5% 
at a sensitivity of 89.4%, 84.4%, and 83.6% for N, S1, and RBD, 
respectively.
IgG in Non-SARS-CoV-2 Infections and SARS-CoV-2 Infections of Various 
Severities
To study how our assay discriminates between antibodies of 
individuals with different laboratory-confirmed viral infec-
tions, antibodies were measured in a cross-sectional pop-
ulation panel (n  =  224), a panel of noncorona ILI patients 
(non-HCoV ILI, n = 74), and non-SARS-CoV-2 corona ILI pa-
tients (HCoV ILI, n = 110) and compared to PCR-confirmed 
COVID-19 patients’ samples. Some of the COVID-19 pa-
tients were admitted to hospital (n  =  50) because of severe 
COVID-19 and these were compared to nonhospitalized 
COVID-19 cases (n = 65). For each of the 3 negative control 
groups the majority of the samples had concentrations below 
the cutoff for all 3 antigens (Figure 3A). The number of false-
positive samples ranged from 5 to 6 out of 404 or 408 samples 
tested for the different antigens. The non-HCoV and HCoV 
ILI panels were from persons infected with multiple different 
non-SARS viruses including 4 different endemic coronavirus 
(Supplementary Table 2). The proportion of false positives 
did not increase by testing the convalescent sera from patients 
with a laboratory (PCR)-confirmed infection with either of 
the 4 seasonal coronaviruses (Figure 3B, and data not shown), 
indicating that the antigens used in the assay are selective 
for SARS-CoV-2–induced antibodies. Comparison of PCR-
confirmed SARS-CoV-2 patients samples shows that all hos-
pitalized patients induced antibodies to N and the majority 
of hospitalized patients induced antibodies to S1 and RBD. 
The majority of the nonhospitalized cases showed antibody 
concentrations above the cutoff for N, whereas around 10% 
of the nonhospitalized patients did not produce antibodies 
above the cutoffs for S1 and RBD. Overall, the concentrations 
of antibodies in serum samples from patients that were hos-
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Figure 1. Assay development and validation A, Different lots of antigen-bead conjugations were used to determine the consistency of the mean fluorescence signal of a 
titrated pooled reference serum. Two different references consisting of pooled sera of COVID-19 patients (Ref 1 and Ref 2) were tested in independent runs designated A, B 
or C. B, The reference and serum samples were serially diluted to test parallelism for reliable quantification of antibody concentrations. C, Samples were tested in 2 inde-
pendent runs by different technicians using different bead and reference batches to test robustness of the triplex assay. Concentrations in AU/mL are shown. Abbreviations: 
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Kinetics of Seroconversion
Following infection, an immune response is initiated, resulting 
in the production of serum antibodies. To study the time be-
tween onset of disease symptoms and the development of anti-
bodies, paired serum samples were collected from the majority 
of patients. Data were separated for patients that were either ad-
mitted to the hospital or not (Figure 4A and 4B). Apart from 
the paired samples from 2 patients that were obtained before 
7 days after onset of disease, all other hospitalized cases showed 
seroconversion for all 3 antigens tested (Figure 4A). In line with 
other reports, hospitalized COVID-19 patients seroconverted 
around day 10 of disease onset. Of 53 nonhospitalized cases, 48 
seroconverted, whereas 5 showed slight increases in concentra-
tions but failed to formally cross the cutoff value for any of the 3 
analytes to be regarded a specific seroconversion. Hospitalized 
patients reached a plateau of antibody production shortly after 
2 weeks from onset of symptoms, which took at least 25 days 
for the nonhospitalized cases (4–10 fold lower slope; Figure 4C 
and 4D). As a consequence of the slower increase of antibody 
concentrations the time to detectable antibodies was delayed, 
especially with respect to antibodies reacting to S1 and RBD. 
The variance in the nonhospitalized cases was high compared 
to the hospitalized cases, which is illustrated by the lower R2 of 
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Figure 2. Ability of the assay to identify COVID-19 patients. A, Control sera (n = 408) and COVID-19 sera (n = 115) collected after day 10 of symptoms were tested and 
compared for concentrations of IgG. Median concentration and 95% confidence intervals are shown. B, The sera tested in (A) were analyzed by ROC. C, The ROC data were 
used to determine Youden J statistic cutoff (lower cutoff) and a specificity-optimized cutoff of at least 98.5% specificity (higher cutoff). Abbreviations: AU, arbitrary unit; IgG, 
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Figure 3. Discrimination of COVID-19 patients with varying severity from a cross-sectional population panel and ILI patients. A, Individuals from the cross-sectional panel 
aged 3–90 years (n = 224), ILI patients with noncoronavirus (n = 75), and non-SARS-CoV-2 seasonal coronavirus-infected ILI patients (n = 109) were compared to hospital-
ized and nonhospitalized COVID-19 patients. Median concentration and 95% confidence intervals and statistical results (adjusted P values of Tukey multiple comparison) 
between the groups are shown. B, Laboratory-confirmed viral infections (see Supplementary Table 2) and concentration data of ILI patients are shown to confirm that the 
assay discriminates SARS-CoV-2–specific antibodies from antibodies induced by various laboratory-confirmed viral infections. Abbreviations: AU, arbitrary unit; COVID-19, 
coronavirus disease 2019; HCoV, human coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; N, nucleoprotein; non-HCoV, noncoronavirus; RBD, receptor 






/jid/article/222/9/1452/5885163 by guest on 19 February 2021
1458 • jid 2020:222 (1 November) • den Hartog et al
Multiplexed Evaluation of Seroconversion of Different Severities of 
COVID-19
The engagement of different structural SARS-CoV-2 pro-
teins in 1 serological determination (multiplex testing) instead 
of 1 protein could improve the sensitivity and the specificity. 
If only 1 analyte is analyzed, the sensitivities for hospitalized 
cases were 94.1%, 94.3%, and 100% for RBD, S1, and N, re-
spectively, using the specificity-optimized cutoff (Table  1). 
Using the ROC Youden J statistic cutoff the sensitivities were 
97.1% for both S1 and RBD and 100% for N. Nonhospitalized 
cases typically had lower concentrations of IgG, which reduced 
the sensitivity: 76.3% for S1 and up to 82.7 % for N using the 
specificity-optimized cutoff. Using the Youden J statistic cutoff, 
the sensitivity increased to 91.3% for S1.
In this multiplex approach an increased sensitivity can be 
obtained by evaluating a sample as positive when either 1 of 
the antibody concentrations determined is higher than the 
set cutoff (logical OR analysis in Table  1). Any combination 
of antigen reached a sensitivity of 100% when N was used in 
hospitalized cases and ranged from 90.4% (S1 or RBD) up to 
95.1% (N or S1 or RBD) using the specificity-optimized cutoff. 
Applying the Youden J statistic cutoff resulted in a sensitivity for 
nonhospitalized cases of at least 92.8% (N or S1) up to 98.8% (N 
or S1 or RBD). The specificity of the Youden J analyses using N 
or S1 or RBD dropped to 90.9%. This specificity is far too low 
for serosurveillance purposes in areas of low prevalence. The 
specificity-optimized cutoff (95.8%–97.8%) is clearly better, 
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Figure 4. Kinetics of antibody production after disease onset in hospitalized and nonhospitalized COVID-19 patients. Paired samples were analyzed to identify changes in 
IgG concentrations in hospitalized (A) and nonhospitalized (B) COVID-19 patients. C, The log-transformed concentration data of the samples shown in (A) and (B) were fitted 
with a 4-parameter nonlinear least squared fit. D, Of each patient with paired samples available, 1 sample was selected randomly and data were fitted to estimate the slope, 
R2 of the fits, and the difference between the fitted lines determined. Abbreviations: AU, arbitrary unit; COVID-19, coronavirus disease 2019; IgG, immunoglobulin G; N, nu-
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population is above 20%. Because in most countries the overall 
COVID-19 seroprevalence is currently under 20%, high speci-
ficity is required to provide reliable seroprevalence estimates (il-
lustrated in Supplementary Table 1). This could be achieved by 
defining a sample positive when at least 2 antibody test results 
in multiplex are above the cutoff. This resulted in a specificity 
of 100% for any of the combinations and both the specificity-
optimized and the Youden J statistic-determined cutoffs (logical 
AND; Table 1). As expected, this increased specificity comes at 
the expense of the sensitivity. Here, if only S1 and RBD are taken 
into consideration, this combination resulted in the highest 
possible sensitivity of 87.3% and 97.1% for nonhospitalized and 
hospitalized patients, respectively.
DISCUSSION
We aimed to develop a high-throughput quantitative assay to 
measure true concentrations of antibodies to spike S1, spike 
RBD, and N of SARS-CoV-2. The assay presented here uses 
a very small sample volume, which can be obtained from, for 
example, fingerstick blood, while retaining highly quantita-
tive output. This bead-based multiplex immunoassay gener-
ates robust results and is able to discriminate COVID-19 with 
different degrees of disease severity, especially from day 10 of 
disease onward. The results of the assay presented here provide 
detailed insight into the performance of the assay in terms of 
parallelism between the references and sera containing different 
concentrations of antibodies. In addition, we show consistency 
of assay results when the same samples are measured on inde-
pendent days, by different investigators using different batches 
of reagents, basically incorporating all potential variability.
Large population studies are in high demand to provide in-
sight into the spread of the virus and the protective status of the 
population, which can be used for policy makers to manage the 
pandemic or lift the lockdown measures [2, 3, 11, 12]. Assays 
results have to be accurate to generate reliable seroprevalence 
data of the general population. In addition to knowing the per-
formance of an assay, we need to understand how the majority 
of infections in the general population relate to the induction 
of detectable antibodies. Our data comparing hospitalized and 
nonhospitalized cases revealed that milder disease results in 
both lower levels of antibodies and later seroconversion, which 
is in line with previous reports [19, 20]. Also, comorbidities may 
play a role in the production of specific serum antibodies fol-
lowing infection, which warrants further study. Approximately 
10% of the nonhospitalized cases in our selection did not show 
any seroconversion at all, indicating that such mild infections 
Table 1. Specificity and Sensitivity of Single and Multiplex Analyses of Seroconversion
Antigen Hospitalized
Specificity optimized Youdens J statistic
Sensitivity, % Specificity, %a Sensitivity, % Specificity, %a
Single      
 N Yes 100 98.7 100 98.2
 N No 82.7  85.2  
 S1 Yes 94.3 99.1 97.1 98.1
 S1 No 76.3  91.3  
 RBD Yes 94.1 98.0 97.1 94.5
 RBD No 78.3  91.6  
OR      
 N or S1 Yes 100 97.8 100 96.3
 N or S1 No 88.0  92.8  
 N or RBD Yes 100 96.7 100 92.8
 N or RBD No 91.7  95.2  
 S1 or RBD Yes 97.1 97.2 97.1 92.7
 S1 or RBD No 90.4  96.4  
 N or S1 or RBD Yes 100 95.8 100 90.9
 N or S1 or RBD No 95.1  98.8  
AND      
 N and S1 Yes 93.5 100 96.8 100
 N and S1 No 70.5  83.3  
 N and RBD Yes 93.5 100 96.8 100
 N and RBD No 69.6  82.3  
 S1 and RBD Yes 91.2 100 97.1 100
 S1 and RBD No 64.6  87.3  
 N and S1 and RBD Yes 90.3 100 96.8 100
 N and S1 and RBD No 59.7  80.5  
Abbreviations: N, nucleoprotein; RBD, receptor binding domain; S1, spike protein subunit 1.
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may not be detected by serological assays. However, assay per-
formance could be improved by adding other SARS-Cov-2 pro-
teins or subunits of these to further improve the sensitivity of 
the assay to detect low seroconversion in some cases.
Essential performance characteristics of assays aiming to 
identify seroprevalence in the population are the specificity 
and sensitivity. The specificity and sensitivity determine the 
positive and negative predictive value (PPV and NPV) of the 
assay given the prevalence of seropositivity in the population 
[21]. In current low-prevalence settings insufficient specificity 
will generate a low PPV, resulting in a significant overestima-
tion of the proportion of seropositive individuals (illustrated in 
Supplementary Table 1). However, the accuracy of the reported 
sensitivity and specificity of an assay also highly depends on the 
patient selection used for this evaluation, for example, using 
sera of severe COVID-19 patients will result in beneficial sta-
tistics of an assay because of the acknowledged higher antibody 
concentration and seroconversion rate [22]. These statistics will 
not apply in a population serosurvey where the majority of per-
sons will not develop severe COVID-19. For this reason, we in-
cluded a heterogeneous group of COVID-19 patients’ samples, 
consequently reducing sensitivity. Scoring samples positive if at 
least 2 of the analytes generated positive results improved the 
specificity of the assay to 100% at a sensitivity > 90%. At a true 
seroprevalence of 5%, this would provide a seroprevalence esti-
mate of 4.5% and therefore would be much more accurate than 
using a single analyte. We recommend transparent reporting of 
underlying assay performance using heterogeneous panels of 
controls and COVID-19 patients. Furthermore, implementa-
tion of international reference materials as being distributed by, 
for example, the National Institute for Biological Standards and 
Control, to facilitate comparison of seroepidemiological data 
between studies and countries is greatly recommended [1, 23].
From an immunological point of view, it needs to be estab-
lished which SARS-CoV-2–specific antibodies correlate with 
protection. Antibodies to RBD of S1 have been shown to asso-
ciate with neutralization of the virus in vitro, and preliminary 
data indicate that the antibodies reported in our assay correlate 
quantitatively with virus neutralization in vitro as well [6]. The 
data presented here show detection of total IgG. Another study 
has shown that IgG subclasses are not equally induced by SARS-
CoV-2 infection, with a bias towards the production of IgG3, at 
least in the first weeks after infection [24]. Infection with SARS-
CoV-2 also induces the production of IgA and IgM, which can 
contribute to protection and in vitro neutralization of the virus, 
but these isotypes are currently not captured by our assay [7, 
8, 25]. Follow-up studies are needed to establish the longevity 
of the production of antibodies, the degree of protection anti-
bodies confer through various Fc receptor-mediated and other 
mechanisms, and how B-cell memory is induced. Such studies 
should also consider different viral loads detected in a patient 
and degree of severity of COVID-19.
In conclusion, we developed a robust multiplex assay to 
detect antibodies to SARS-CoV-2 in small blood volumes. 
Our study is unique in validating the assay against HCoV 
and non-HCoV ILI panels. Because of the differences in se-
roconversion rates and quantitative antibody concentrations 
among nonhospitalized COVID-19 cases, which represents 
the majority of patients in the general population, further 
investigation is required to improve assay performance for 
serosurveys in general. We show the advantages of multi-
plexed analysis in determining seroconversion and provide a 
framework for reliable seroprevalence estimates in different 
settings.
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